Recombinant Anti-Elav-type RNA-binding protein ETR3 antibody [EPR13374-2] (ab186430)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR13374-2] to Elav-type RNA-binding protein ETR3
- Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IP
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Elav-type RNA-binding protein ETR3 antibody [EPR13374-2]
See all Elav-type RNA-binding protein ETR3 primary antibodies -
Description
Rabbit monoclonal [EPR13374-2] to Elav-type RNA-binding protein ETR3 -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IPmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human fetal liver, K562, HeLa, MCF7, C6 and NIH 3T3 lysates; Human brain tissue; rat lung tissue; MCF7 and HeLa cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR13374-2 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab186430 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/270.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB | (1) |
1/1000 - 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 54 kDa).
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
ICC/IF | (1) |
1/500.
|
IP |
1/50 - 1/70.
|
Notes |
---|
Flow Cyt (Intra)
1/270. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 54 kDa). |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
ICC/IF
1/500. |
IP
1/50 - 1/70. |
Target
-
Function
RNA-binding protein implicated in the regulation of several post-transcriptional events. Involved in pre-mRNA alternative splicing, mRNA translation and stability. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of TNNT2 in embryonic, but not adult, skeletal muscle. Activates TNNT2 exon 5 inclusion by antagonizing the repressive effect of PTB. Acts as both an activator and repressor of a pair of coregulated exons: promotes inclusion of the smooth muscle (SM) exon but exclusion of the non-muscle (NM) exon in actinin pre-mRNAs. Promotes inclusion of exonS 21 and exclusion of exon 5 of the NMDA receptor R1 pre-mRNA. Involved in the apoB RNA editing activity. Increases COX2 mRNA stability and inhibits COX2 mRNA translation in epithelial cells after radiation injury (By similarity). Modulates the cellular apoptosis program by regulating COX2-mediated prostaglandin E2 (PGE2) expression (By similarity). Binds to (CUG)n triplet repeats in the 3'-UTR of transcripts such as DMPK. Binds to the muscle-specific splicing enhancer (MSE) intronic sites flanking the TNNT2 alternative exon 5. Binds preferentially to UG-rich sequences, in particular UG repeat and UGUU motifs. Binds to apoB mRNA, specifically to AU-rich sequences located immediatly upstream of the edited cytidine. Binds AU-rich sequences in the 3'-UTR of COX2 mRNA (By similarity). Binds to an intronic RNA element responsible for the silencing of exon 21 splicing (By similarity). Binds to (CUG)n repeats. -
Tissue specificity
Expressed in frontal cortex. Isoform 1 is expressed in brain and lung. Isoform 2 is expressed in heart, brain, placenta, lung, liver, kidney, skeletal muscle and pancreas. Isoform 4 is expressed in heart, lung, skeletal muscle, kidney and pancreas. -
Sequence similarities
Belongs to the CELF/BRUNOL family.
Contains 3 RRM (RNA recognition motif) domains. -
Developmental stage
Isoform 1 is expressed in fetal brain. Isoform 2 is expressed in fetal heart, brain, thymus, lung, liver, skeletal muscle, kidney and spleen. Isoform 4 is expressed in fetal heart, brain, thymus, lung and skeletal muscle. -
Cellular localization
Nucleus. Cytoplasm. Accumulates in the cytoplasm after ionizing radiation (By similarity). Colocalizes with APOBEC1 and A1CF. RNA-binding activity is detected in both nuclear and cytoplasmic compartments. - Information by UniProt
-
Database links
- Entrez Gene: 10659 Human
- Entrez Gene: 14007 Mouse
- Entrez Gene: 29428 Rat
- Omim: 602538 Human
- SwissProt: O95319 Human
- SwissProt: Q9Z0H4 Mouse
- SwissProt: Q792H5 Rat
- Unigene: 309288 Human
see all -
Alternative names
- Bruno-like protein 3 antibody
- BRUNOL3 antibody
- Cardiac elav type RNA binding protein antibody
see all
Images
-
All lanes : Anti-Elav-type RNA-binding protein ETR3 antibody [EPR13374-2] (ab186430) at 1/5000 dilution
Lane 1 : Human fetal liver lysate
Lane 2 : K562 cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : MCF7 cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 54 kDa
Observed band size: 54 kDa -
ab186430 staining Elav-type RNA-binding protein ETR3 in HeLa (human cervix adenocarcinoma) cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% PFA and permeabilised with 0.1% triton X-100. Samples were incubated with primary antibody at a dilution of 1/500. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody at a dilution of 1/1000. DAPI was used as a nuclear counterstain.
Negative control 1:PBS only.
-
All lanes : Anti-Elav-type RNA-binding protein ETR3 antibody [EPR13374-2] (ab186430) at 1/5000 dilution
Lane 1 : C6 cell lysate
Lane 2 : NIH 3T3 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 54 kDa
Observed band size: 54 kDa -
Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling Elav-type RNA-binding protein ETR3 with ab186430 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded rat lung tissue labeling Elav-type RNA-binding protein ETR3 with ab186430 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
-
Immunofluorescent analysis of 4% paraformaldehyde-fixed MCF7 cells labeling Elav-type RNA-binding protein ETR3 with ab186430 at 1/500 dilution, followed by Goat anti rabbit IgG (Alexa Fluor® 555) secondary antibody at 1/200 dilution. Counter stained with Dapi (blue).
-
Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling Elav-type RNA-binding protein ETR3 with ab186430 at 1/500 dilution, followed by Goat anti rabbit IgG (Alexa Fluor® 555) secondary antibody at 1/200 dilution. Counter stained with Dapi (blue).
-
Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed HeLa cells labeling Elav-type RNA-binding protein ETR3with ab186430 at 1/270 dilution (red) compared to a Rabbit monoclonal IgG isotype control (green), followed by Goat anti rabbit IgG (FITC) secondary antibody at 1/150 dilution.
-
Western blot analysis of Elav-type RNA-binding protein ETR3 in HeLa cell lysate immunoprecipitated with ab186430 at 1/50 dilution (Lane 1). Lane 2: PBS instead of HeLa lysate.
Secondary antibody: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (6)
ab186430 has been referenced in 6 publications.
- Guo D et al. ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2. Cell Cycle 22:117-130 (2023). PubMed: 35941836
- Wang D et al. GAS5 knockdown alleviates spinal cord injury by reducing VAV1 expression via RNA binding protein CELF2. Sci Rep 11:3628 (2021). PubMed: 33574559
- Lukosiute-Urboniene A et al. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer. World J Gastroenterol 25:205-219 (2019). PubMed: 30670910
- Yeung YT et al. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis N/A:N/A (2019). PubMed: 31241130
- Wang S et al. RNA Binding Proteins Control Transdifferentiation of Hepatic Stellate Cells into Myofibroblasts. Cell Physiol Biochem 48:1215-1229 (2018). PubMed: 30045014
- Wang J et al. miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. Biomed Pharmacother 101:406-413 (2018). WB . PubMed: 29501762